WHO Endorses New Obesity Drugs but Stresses Limits and Inequalities
The World Health Organization on Monday presented its first-ever global guideline on the use of GLP-1 therapies for adults living with obesity, calling the medicines a transformative development while also warning they are not a silver bullet for a deeply social and economic problem. The guidance – described by senior WHO officials as marking a “new chapter” in obesity care – recommends that certain GLP-1 drugs may be used long-term in adults with obesity, but frames that clinical endorsement inside a web of caveats about safety data, health-system readiness and stark inequalities of access.
The headline advice is straightforward but deliberately modest. WHO issues two conditional recommendations – first, that GLP-1 receptor agonists such as liraglutide, semaglutide and tirzepatide may be offered to adults with a body-mass index (BMI) of 30 or more for long-term treatment of obesity (pregnant women are excluded) – second, that these medicines should be prescribed alongside intensive behavioural support – structured diet, exercise and follow-up – rather than as a lone, quick-fix intervention. The organisation made clear the recommendation is conditional because, despite strong trial evidence of weight loss and metabolic benefit, important questions remain about long-term safety, maintenance and what happens when treatment stops.
Why does WHO now regard the drugs as safe enough to recommend – albeit cautiously? The agency’s judgement rests on a growing body of high-quality randomised trial evidence showing that GLP-1 receptor agonists produce large, reproducible reductions in body weight and improve markers of metabolic health. These therapies were originally developed for diabetes and have demonstrated benefits beyond weight loss in people with type 2 diabetes – better blood-sugar control, fewer cardiovascular and kidney complications and, in some settings, lower mortality. Those benefits, together with robust trial data on magnitude of weight loss, underpin WHO’s view that GLP-1s are an important tool in treating obesity as a chronic disease rather than a moral failing.
But the endorsement is not an unqualified safety stamp. WHO emphasises the available evidence is incomplete on several fronts – most trials to date have been of limited duration compared with the lifetime course of obesity, there are unanswered questions about the risks and benefits of indefinite, possibly lifelong, therapy and the consequences of stopping treatment – where substantial weight regain is common – remain worrying. The guideline therefore calls the recommendation conditional, based on substantial short-to-medium-term benefits but tempered by uncertainty over long-term effects and by real-world issues such as drug quality, counterfeit products, and system capacity to monitor and support patients.
There are practical safety reasons for the restrictions WHO sets. The agency excludes pregnant women, flags falsified products as a serious hazard in informal markets, and stresses prescription and regulated distribution by qualified health professionals. Gastrointestinal side effects are common with GLP-1s; rare but serious events have been debated in the literature and the surveillance systems that would detect rare harms are patchy in many countries. WHO’s prescription is therefore as much about strengthening systems for safe delivery – screening, counselling, long-term follow-up and pharmacovigilance – as it is about saying “give the drug.”
Perhaps the most striking part of WHO’s approach is its insistence that medicines alone will not reverse the obesity pandemic. The guidance is embedded in a three-pillar strategy – reshape food and physical environments at population level, protect those at high risk with targeted early interventions, and ensure access to lifelong, person-centred care. Without such a shift, WHO warns, GLP-1 therapies risk becoming the preserve of wealthier countries and wealthier people, widening health inequities rather than narrowing them. WHO’s modelling and repeated warnings from clinicians – suggests that, under current production and pricing conditions, fewer than 10% of people globally who could benefit will be able to access these drugs by 2030. That, the agency says, is a moral and practical problem that requires pooled procurement, tiered pricing and voluntary licensing.
The reaction from independent experts has been broadly supportive of WHO’s tone – many welcome a carefully balanced endorsement that recognises both the drugs’ clinical value and the systemic challenges they pose. Commentators have praised the guideline for treating obesity as a chronic disease requiring long-term management, while also noting the need for clearer evidence about lifelong use, affordability, and priority-setting in resource-constrained systems. In short – medicine matters, but so do politics, economics and social policy.
What does this mean in practice? For clinicians, the guideline offers an evidence-based framework to consider GLP-1s for eligible patients, while insisting on psychological and lifestyle supports and careful monitoring. For governments and health services, it is a call to invest in systems – training, procurement, surveillance and to confront pricing and production bottlenecks. For pharmaceutical companies, it is a near-explicit invitation to step up manufacturing, lower prices and cooperate on equitable licensing. And for individuals, the message is nuanced: a new, effective option now exists, but it is not a shortcut to population health, nor a cure for the social drivers of obesity.
WHO’s guideline changes the conversation by legitimising pharmaceutical therapy as part of comprehensive obesity care. But by framing its endorsement as conditional and by foregrounding equity, safety systems and behavioural support, the agency has tried to ensure the moment is not reduced to a celebrity-fuelled fad for weight loss drugs. If the past two years taught policymakers anything, it is that a medical breakthrough without an equitable delivery plan risks becoming simply another inequality amplifier. The question now is whether the global community will heed WHO’s call to make this “new chapter” a fair one.
Photo – Serena Williams talks about her use of GLP-1s to lose weight in new TV, billboard and online ads for the telehealth provider Ro. Ro